CN-118766927-B - New application of ganciclovir

Abstract

The present invention provides a novel use of ganciclovir for the treatment, alleviation and/or alleviation of non-allergic rhinitis characterized by eosinophilia. The study of the invention shows that the nasal allergy symptoms of NARES patients are obviously relieved by using ganciclovir, and the antiallergic medicine with poor original curative effect can play a role again, so that the nasal symptoms of refractory NARES patients are effectively and permanently improved, and the rhinitis symptoms are effectively improved.

Inventors

• XIAO HONGJUN
• CHEN JIANJUN
• ZHOU YUE
• GAO PEI
• Hu Qianxue
• ZOU ZHIXIN
• Huo Bingyue

Assignees

• 华中科技大学同济医学院附属协和医院

Dates

Publication Date

20260505

Application Date

20240717

Claims (5)

1. 1. Use of ganciclovir in the manufacture of a medicament for the treatment, alleviation and/or alleviation of non-allergic rhinitis with eosinophilia syndrome.
2. 2. The use according to claim 1, wherein ganciclovir is administered in a daily dose of 500mg to 1000 mg.
3. 3. The use according to claim 1, wherein the ganciclovir is administered orally.
4. 4. The use according to claim 3, wherein the ganciclovir is administered twice daily at a fixed dose of 250mg to 500mg each time.
5. 5. The use according to claim 4, wherein ganciclovir is administered continuously for at least one course of treatment, each course lasting for at least two weeks.

Description

New application of ganciclovir Technical Field The present invention relates to the field of medicine, in particular to a new use of ganciclovir, more in particular to the use of ganciclovir in a medicament for the treatment, alleviation and/or alleviation of diseases related to non-allergic rhinitis characterized by eosinophilia, and/or to chronic inflammatory diseases of the nasal sinus mucosa. Background The non-allergic rhinitis with eosinophilia syndrome (NARES) is also called eosinophilia non-allergic rhinitis (eosinophilic nonallergic rhinitis), and is characterized by eosinophilia, and the pathogenesis is unknown. The main symptoms are similar to allergic rhinitis and are sneeze, nasal itching, nasal obstruction and clear nasal discharge, but the symptoms are heavy, and are often accompanied by hyposmia or loss, so that the patients often have difficulty in speaking the cause of symptom onset. Nasal examination also showed no characteristic change, nasal mucosa was either chronically hyperemic or pallidum, and nasal secretion smears were found to have a large number of eosinophils, which was judged to be more than 20% of eosinophils and monocytes (excluding epithelial cells) in nasal secretions, with a peripheral blood eosinophil count >5%, and allergen detection was negative. The nasal secretion without allergic reaction has increased eosinophilia, and has high reactivity and symptom of nasal disease, so that NARES can be diagnosed. Clinically, it is required to identify the disease with vascular motility rhinitis and allergic rhinitis. Because eosinophilia type non-allergic rhinitis has a plurality of induction factors, the pathogenesis is complicated, and comprehensive measures should be taken in the treatment. Improving working condition and environment, mastering life rhythm, stabilizing emotion, and avoiding excessive fatigue and tension. The medicines are selected timely according to the change of the disease condition, and the current clinical common medicine treatment method is the same as allergic rhinitis, wherein the first-line treatment medicines comprise nasal glucocorticoid (for short, nasal hormone), second-generation oral and nasal antihistamines and oral leukotriene receptor antagonists, and the second-line treatment medicines comprise oral glucocorticoid and the like. Ganciclovir (Ganciclovir; GCV, chemical formula C 9H13N5O4, chemical formula structure shown in figure 7) is an effective antiviral drug for the treatment of DNA viruses, such as cytomegalovirus and herpes virus infections. The main mechanism is that GCV is phosphorylated by viral thymidine kinase and enters cells, inhibiting DNA polymerase and thus inhibiting viral replication. From the point of view of the pharmaceutical mechanism known at present, it does not have an effect on eosinophilic inflammation. Disclosure of Invention (One) solving the technical problems The invention aims to provide a new application of ganciclovir in treating the related diseases in the aspect of treating the related diseases in the prior art, wherein the diseases are related to non-allergic rhinitis characterized by eosinophilia and/or the problems related to chronic inflammatory diseases of nasal sinus mucosa. (II) technical scheme According to an aspect of the present invention there is provided a novel use of ganciclovir in a medicament for the treatment, alleviation and/or alleviation of a disease associated with non-allergic rhinitis characterised by eosinophilia. Further, the disease associated with non-allergic rhinitis characterized by eosinophilia includes non-allergic rhinitis with eosinophilia syndrome. Further, the ganciclovir is administered in a daily dose of about 500mg to about 1000 mg. Further, the ganciclovir is administered orally. Further, the ganciclovir is administered twice daily at a fixed dose of about 250mg to about 500mg each time. Further, the ganciclovir is administered continuously for at least one course of treatment, each course lasting for at least two weeks. According to another aspect of the present invention, there is provided a method of evaluation based on the use of ganciclovir as described above in a medicament for the treatment, alleviation and/or alleviation of a disease associated with non-allergic rhinitis characterized by eosinophilia, characterized in that AR patients with poor efficacy of administration of conventional antiallergic drugs are divided into classical treatment groups and ganciclovir treatment groups, wherein the classical treatment groups are administered an oral antihistamine and the ganciclovir treatment groups are administered ganciclovir for two weeks, twice daily, with a fixed dose of about 500mg each time. Further, the severity of all syndromes was assessed by visual analog scale, ranging from asymptomatic 0 to the most severe symptoms conceivable 100; the nasal obstruction, nasal itching, sneeze and nasal discharge are respectively scored, and the nasal symptoms are to